Financial Ratios Ovoca Bio plc Euronext Dublin
Equities
OVXA
IE0006649010
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0100 EUR | -.--% |
|
-.--% | - |
| Feb. 24 | Talisman Metals acquires two Morocco copper licences for GBP16,000 | AN |
| Feb. 24 | Talisman Metals Starts Exploration at Fougnar Copper-silver Project in Morocco | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -6.37 | -21.67 | -20.51 | -8.24 | -5.08 | |||||
Return on Total Capital | -6.5 | -22.9 | -23.54 | -10.47 | -6.82 | |||||
Return On Equity % | -10.94 | -32.81 | -53.28 | -100.71 | -0.13 | |||||
Return on Common Equity | -11.16 | -32.81 | -53.28 | -100.71 | -0.13 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 23.51 | 5.24 | 2.81 | 3.59 | 4.47 | |||||
Quick Ratio | 22.2 | 5.17 | 2.79 | 3.58 | 4.32 | |||||
Operating Cash Flow to Current Liabilities | -4.34 | -3.26 | -2.92 | 1.15 | -1.91 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | - | - | - | - | - | |||||
Total Debt / Total Capital | - | - | - | - | - | |||||
Total Liabilities / Total Assets | 2.55 | 9.08 | 18.82 | 27.88 | 22.38 | |||||
EBIT / Interest Expense | -137.81 | -279.05 | -101.72 | -169.8 | - | |||||
EBITDA / Interest Expense | -133.38 | -275.05 | -92.74 | -109.8 | - | |||||
(EBITDA - Capex) / Interest Expense | -134 | -275.71 | -92.74 | -109.8 | - | |||||
Total Debt / EBITDA | - | - | - | - | - | |||||
Net Debt / EBITDA | 5.04 | 1.14 | 1.02 | 6.08 | -49.14 | |||||
Total Debt / (EBITDA - Capex) | - | - | - | - | - | |||||
Net Debt / (EBITDA - Capex) | 5.01 | 1.14 | 1.02 | 6.08 | -49.14 | |||||
Growth Over Prior Year | ||||||||||
EBITDA, 1 Yr. Growth % | -4.77 | 170.67 | -37.38 | -84.02 | -109.29 | |||||
EBITA, 1 Yr. Growth % | -4.77 | 170.6 | -37.32 | -84.05 | -54.64 | |||||
EBIT, 1 Yr. Growth % | -4.75 | 165.76 | -32.3 | -78.6 | -70.67 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 21.87 | 126.36 | 6.96 | -9.05 | -99.94 | |||||
Net Income, 1 Yr. Growth % | 48.88 | 134.38 | 2.5 | -16.22 | -84.13 | |||||
Normalized Net Income, 1 Yr. Growth % | 81.21 | 131.72 | 0.63 | -84.7 | -99.63 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 52.97 | 129.75 | 6.96 | -9.02 | -99.94 | |||||
Inventory, 1 Yr. Growth % | 32.51 | -65.06 | -54.26 | - | - | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 133.33 | 157.14 | -100 | - | - | |||||
Total Assets, 1 Yr. Growth % | -21.53 | -22.41 | -36.33 | -63.13 | -23.47 | |||||
Tangible Book Value, 1 Yr. Growth % | -19.32 | -39.34 | -61.81 | -22.06 | -17.63 | |||||
Common Equity, 1 Yr. Growth % | -16.97 | -27.61 | -43.15 | -67.24 | -17.63 | |||||
Cash From Operations, 1 Yr. Growth % | -2.72 | 107.3 | 18.01 | -121.59 | -201.88 | |||||
Capital Expenditures, 1 Yr. Growth % | - | 40 | - | - | - | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -28.53 | 96.83 | -8.09 | -102.44 | -1.02K | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -28.51 | 97.32 | -8.56 | -102.59 | -974.75 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
EBITDA, 2 Yr. CAGR % | 4.69 | 60.54 | 30.19 | -69.17 | -87.82 | |||||
EBITA, 2 Yr. CAGR % | 4.69 | 60.53 | 30.24 | -69.18 | -73.1 | |||||
EBIT, 2 Yr. CAGR % | 6.36 | 59.1 | 34.13 | -61.94 | -74.95 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 7.76 | 66.09 | 55.6 | -1.37 | -97.69 | |||||
Net Income, 2 Yr. CAGR % | -0.43 | 86.8 | 55 | -7.33 | -63.54 | |||||
Normalized Net Income, 2 Yr. CAGR % | 41.35 | 104.91 | 52.7 | -60.76 | -97.62 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 16.59 | 87.47 | 56.76 | -1.35 | -97.69 | |||||
Inventory, 2 Yr. CAGR % | 22.59 | -31.95 | -60.02 | - | - | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 52.75 | 144.95 | - | - | - | |||||
Total Assets, 2 Yr. CAGR % | -6.55 | -21.98 | -29.71 | -51.55 | -46.88 | |||||
Tangible Book Value, 2 Yr. CAGR % | 1.24 | -30.04 | -51.87 | -45.44 | -19.88 | |||||
Common Equity, 2 Yr. CAGR % | 0.23 | -22.47 | -35.85 | -56.85 | -48.06 | |||||
Cash From Operations, 2 Yr. CAGR % | -13.75 | 42.01 | 56.4 | -49.52 | -53.1 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 22.07 | 18.61 | 34.5 | -85.03 | -52.61 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 22.04 | 18.77 | 34.32 | -84.6 | -52.37 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
EBITDA, 3 Yr. CAGR % | 43.25 | 43.69 | 17.3 | -36.4 | -79.33 | |||||
EBITA, 3 Yr. CAGR % | 43.23 | 43.67 | 17.33 | -36.42 | -64.94 | |||||
EBIT, 3 Yr. CAGR % | 44.75 | 44.33 | 19.67 | -27.25 | -65.1 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 115.07 | 38.01 | 43.43 | 30.1 | -91.7 | |||||
Net Income, 3 Yr. CAGR % | 83.03 | 32.46 | 52.93 | 26.26 | -48.54 | |||||
Normalized Net Income, 3 Yr. CAGR % | 128.82 | 66.66 | 61.67 | -29.07 | -91.7 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 112.94 | 46.17 | 55.48 | 30.76 | -91.71 | |||||
Inventory, 3 Yr. CAGR % | - | -19.32 | -40.39 | - | - | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 32.64 | 81.71 | - | - | - | |||||
Total Assets, 3 Yr. CAGR % | -5.35 | -12.17 | -27.09 | -43.31 | -43.57 | |||||
Tangible Book Value, 3 Yr. CAGR % | -14.81 | -14.65 | -42.82 | -43.48 | -37.41 | |||||
Common Equity, 3 Yr. CAGR % | -6.09 | -10.07 | -30.09 | -48.72 | -46.47 | |||||
Cash From Operations, 3 Yr. CAGR % | 31.85 | 15.53 | 33.51 | -19.17 | -36.21 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -5.11 | 43.14 | 8.94 | -64.67 | -40.9 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -5.23 | 43.24 | 8.85 | -63.97 | -40.8 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
EBITDA, 5 Yr. CAGR % | 11.96 | 27.14 | 37.87 | -22.37 | -53.07 | |||||
EBITA, 5 Yr. CAGR % | 11.15 | 26.52 | 37.88 | -22.38 | -35.57 | |||||
EBIT, 5 Yr. CAGR % | 11.86 | 26.87 | 40.41 | -15.31 | -35.98 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 0.85 | 40.48 | 88.95 | 20.66 | -72.49 | |||||
Net Income, 5 Yr. CAGR % | 1.01 | 41.68 | 71.25 | 14.82 | -13.82 | |||||
Normalized Net Income, 5 Yr. CAGR % | 9.84 | 34.59 | 94.64 | -6.54 | -70.07 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 0.55 | 40.38 | 88.38 | 24.89 | -71.14 | |||||
Inventory, 5 Yr. CAGR % | 42.36 | 10.91 | - | - | - | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -64.99 | -58.8 | - | - | - | |||||
Total Assets, 5 Yr. CAGR % | -2.6 | -9.01 | -15.97 | -30.77 | -35.76 | |||||
Tangible Book Value, 5 Yr. CAGR % | -8.38 | -18.57 | -32.2 | -28.64 | -34.56 | |||||
Common Equity, 5 Yr. CAGR % | -2.86 | -10.56 | -19.37 | -32.96 | -37.92 | |||||
Cash From Operations, 5 Yr. CAGR % | 17.97 | 61.85 | 41.17 | -17.04 | -12.14 | |||||
Capital Expenditures, 5 Yr. CAGR % | - | 69.52 | - | - | - | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 18.28 | 43.51 | 9.1 | -41.98 | -21.91 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 18.36 | 43.83 | 8.96 | -41.3 | -21.79 |
- Stock Market
- Equities
- TLM Stock
- OVXA Stock
- Financials Ovoca Bio plc
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















